Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

791 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, Michel J, Focan CH, Ries F, Gobert PH, Closon-Dejardin MT, Dolci S, Rouas G, Paesmans M, Lobelle JP, Isola J, Piccart MJ. Di Leo A, et al. Ann Oncol. 2001 Aug;12(8):1081-9. doi: 10.1023/a:1011669223035. Ann Oncol. 2001. PMID: 11583189 Free article. Clinical Trial.
The predictive value of HER2 in breast cancer.
Piccart M, Lohrisch C, Di Leo A, Larsimont D. Piccart M, et al. Among authors: di leo a. Oncology. 2001;61 Suppl 2:73-82. doi: 10.1159/000055405. Oncology. 2001. PMID: 11694791 Review.
The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions.
Ferreira Filho AF, Di Leo A, Paesmans M, Beauduin M, Vindevoghel A, Michel J, Focan C, Awada A, Cardoso F, Dolci S, Bartholomeus S, Piccart MJ. Ferreira Filho AF, et al. Among authors: di leo a. Ann Oncol. 2002 Mar;13(3):416-21. doi: 10.1093/annonc/mdf051. Ann Oncol. 2002. PMID: 11996473 Free article. Clinical Trial.
Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients.
Bernard-Marty C, Mano M, Paesmans M, Accettura C, Munoz-Bermeo R, Richard T, Kleiber K, Cardoso F, Lobelle JP, Larsimont D, Piccart MJ, Di Leo A. Bernard-Marty C, et al. Among authors: di leo a. Ann Oncol. 2003 May;14(5):693-8. doi: 10.1093/annonc/mdg204. Ann Oncol. 2003. PMID: 12702521 Free article.
791 results